FDA eases REMS labeling for Travere’s Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics’ Filspari
Where Today's News Shapes Tomorrow
